Learning Objectives:

• Upon completion, participants will be able to: 
  • describe the clinical applications, strengths, and limitations of modern diagnostic technologies, including multiplex syndromic panels, MALDI-TOF mass spectrometry, and next-generation sequencing (NGS), to select the most appropriate test for complex infectious cases.
  • apply the 2024 IDSA/ASM diagnostic stewardship guidelines for optimal specimen collection (tissue vs. swabs) and interpretation, distinguishing between colonization/contamination and true infection, particularly in blood and urine cultures.
  • incorporate recent practice-changing evidence into clinical decision-making, including the use of novel antimicrobial agents for resistant pathogens (CRAB, MRSA), optimized treatment durations, oral step-down therapy for bacteremia, and updated vaccination strategies.

Patrick J. Kenney, DO, FACOI (he/him/his), Vice Chair and Fellowship Program Director, Department of Infectious Diseases, Cleveland Clinic Florida

Learning Objectives:

• List the 4 major families of hemorrhagic fever viruses (HFVs).
• Recognize key clinical features of VHFs (Viral Hemorrhagic Fevers).
• Apply diagnostic and isolation protocols for suspected cases. Initiate supportive care and targeted therapies (e.g., ribavirin).

MarkAlain Déry, DO, MPH, FACOI (he/him/his), Chief Innovation Officer, Access Health Louisiana

Learning Objectives:

• Upon completion, participantswill be able to:
  • recognize the clinical presentations and red flags of bacterial meningitis, viral encephalitis, and cryptococcal meningitis in high-risk populations.
  • apply evidence-based diagnostic algorithms including appropriate use of CT imaging, lumbar puncture, CSF analysis, and advanced molecular testing.
  • prescribe appropriate empiric and pathogen-specific antimicrobial therapy with correct dosing and duration for common CNS infections.

Patrick J. Kenney, DO, FACOI (he/him/his), Vice Chair and Fellowship Program Director, Department of Infectious Diseases, Cleveland Clinic Florida

Learning Objectives:

• Recognize Common Etiologies: Identify the most common bacterial, viral, and parasitic causes of gastrointestinal infections and their distinguishing clinical features.
• Understand Diagnostic Approaches: Outline the appropriate diagnostic tools, including stool studies, PCR testing, and imaging, to confirm the etiology of GI infections.
• Develop Treatment Strategies: Formulate evidence-based management plans, including supportive care, antibiotic use, and specific therapies for conditions like C. difficile colitis. Emphasize Prevention: Highlight key prevention strategies such as vaccination, food safety practices, and infection control measures to reduce the incidence of GI infectious diseases. List the most common causative organisms of infective endocarditis (IE) and their clinical associations. Apply the Modified Duke Criteria to classify a case as "definite," "possible," or "rejected" IE. Identify patients and procedures that warrant antibiotic prophylaxis for lE, per current guidelines (AHA/ACC, ESC). Prescribe the correct antibiotic regimen for IE prophylaxis based on patient allergies and procedure type.

MarkAlain Déry, DO, MPH, FACOI (he/him/his), Chief Innovation Officer, Access Health Louisiana

Learning Objectives:

• Upon completion of this educational activity, participants will be able to utilize current ATS/IDSA guidelines to diagnose, assess severity, and select appropriate empiric antibiotic therapy for community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) in adult patients.
• Upon completion of this educational activity, participants will be able to select appropriate treatment regimens for drug-susceptible and drug-resistant tuberculosis, including NEW 2025 shortened regimens (4-month DS-TB, 6-month BPaL/BPaLM) based on patient eligibility and drug susceptibility testing.
• Upon completion of this educational activity, participants will be able to recognize and apply major practice changes from recent guidelines (2019-2025), including elimination of HCAP category, shortened treatment durations, and new all-oral regimens for drug-resistant tuberculosis.

Patrick J. Kenney, DO, FACOI (he/him/his), Vice Chair and Fellowship Program Director, Department of Infectious Diseases, Cleveland Clinic Florida

Learning Objectives:

• Understand "Undetectable = Untransmittable (U=U)" and its significance in eliminating HIV transmission risk.
• Understand the importance of starting antiretroviral therapy (ART) early to achieve viral suppression, improve outcomes, and prevent transmission.
• Learn to monitor HIV therapy with regular viral load testing for virologic suppression and CD4 count for immune status assessment. Identify the role of pre-exposure prophylaxis (PrEP) in preventing HIV infection and its e fectiveness when taken consistently. Determine which populations will most likely benefit from PrEP and how to implement it in clinical practice. Explore the use of doxycycline post-exposure prophylaxis (Doxy-PEP) to prevent bacterial STIs in high-risk individuals. Discuss its integration into HIV prevention strategies, particularly for patients on PrEP or living with HIV.

MarkAlain Déry, DO, MPH, FACOI (he/him/his), Chief Innovation Officer, Access Health Louisiana

Learning Objectives:

• Upon completion of this activity, the audience member will be better able to: 
  • delineate various immunodeficiencies when given a history and/or physical findings.
  • provide a framework for the evaluation of primary immune deficiencies that may affect adults
  • review the Immune Response and complement cascade using a case-based approach

Bryan L. Martin, DO, MACOI (he/him/his), Emeritus Professor of Medicine, The Ohio State University

Learning Objectives:

• Upon completion of this activity, the audience member will be better able to: 
  • recognize and appropriately treat, systemic allergic disorders.
  • understand and be prepared to utilize the latest guidelines for the treatment of anaphylaxis.
  • compare and contrast anaphylactic and anaphylactoid reactions.

Bryan L. Martin, DO, MACOI (he/him/his), Emeritus Professor of Medicine, The Ohio State University

Learning Objectives:

• Upon completion of this activity, the audience member will have reviewed the recognition and treatment of allergic skin disorders, to include 
  • Urticaria and Angioedema
  • Hereditary Angioedema
  • Atopic Dermatitis and Allergic Contact Dermatiti

Bryan L. Martin, DO, MACOI (he/him/his), Emeritus Professor of Medicine, The Ohio State University

Learning Objectives:

• Learn the Asthma Guidelines EPR 3 vs EPR 4
• Be able to classify asthma severity Be able to determine asthma control
• Be able to successfully treat asthma Be able to improve patient outcomes

Jonathan M. Horbal, DO, FACOI, Physician, Midland and Bay Allergy Clinics

Learning Objectives:

• Understand rhinitis and how to classify it
• Review the difference between allergic and non-allergic rhinitis
• Review current guidelines for treating sinusitis

Jonathan M. Horbal, DO, FACOI, Physician, Midland and Bay Allergy Clinics

Learning Objectives:

• Understand paradigm shift in food allergy thoughts
• Understand the proper testing modalities for food testing
• Review common food allergy mimickers

Jonathan M. Horbal, DO, FACOI, Physician, Midland and Bay Allergy Clinics

Learning Objectives:

• Review hypersensitivity reactions and common cases for each hypersensitivity class
• Understand basic pathophysiology of drug reactions
• Review skin presentations of drug reactions

Jonathan M. Horbal, DO, FACOI, Physician, Midland and Bay Allergy Clinics